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BACKGROUND: A British randomised study of gemcitabine plus cisplatin (GC) combination showed promising results in biliary tract
cancer (BTC) patients. In our study, we evaluated the efficacy and safety of this combination compared with gemcitabine alone (G) in
Japanese BTC patients.
METHODS: Overall, 84 advanced BTC patients were randomised to either cisplatin 25mgm
 2 plus gemcitabine 1000mgm
 2 on days
1, 8 of a 21-day cycle (GC-arm), or single-agent gemcitabine 1000mgm
 2 on days 1, 8 and 15 of a 28-day cycle (G-arm). Treatments
were repeated for at least 12 weeks until disease progression or unacceptable toxicity occurred, up to a maximum of 48 weeks.
RESULTS: A total of 83 patients were included in the analysis. For the GC and G-arms, respectively, the 1-year survival rate was 39.0 vs
31.0%, median survival time 11.2 vs 7.7 months, median progression-free survival time 5.8 vs 3.7 months and overall response rate
19.5 vs 11.9%. The most common grade 3 or 4 toxicities (GC-arm/G-arm) were neutropenia (56.1%/38.1%), thrombocytopenia
(39.0%/7.1%), leukopenia (29.3%/19.0%), haemoglobin decrease (36.6%/16.7%) and g-GTP increase (29.3%/35.7%).
CONCLUSIONS: Gemcitabine plus cisplatin combination therapy was found to be effective and well tolerated, suggesting that it could
also be a standard regimen for Japanese patients.
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Although biliary tract cancer (BTC) is a rare type of cancer
throughout the world, it is more prevalent in East Asia and Latin
America than in other countries (Matsuda and Marugame, 2007;
Randi et al, 2009). According to ‘Demographic Statistics in Japan
(2009)’ (compiled by the Statistics and Information Department,
Minister’s Secretariat, Ministry of Health, Labour, and Welfare
(MHLW)), the number of deaths due to BTC was 17311 in 2007,
making this cancer the sixth leading cause of cancer death
in Japan.
Despite great progress in diagnostic imaging, most cases of BTC
are diagnosed as advanced and inoperable. Even if the tumour is
not locally advanced, the primary tumour site is often contiguous
with vital organs such as the liver, pancreas, or duodenum, or with
major vessels such as the portal vein or hepatic artery. This
anatomical peculiarity precludes resection of tumours in many
cases. Furthermore, even if curative-intent surgical resection is
performed, the cancer often relapses due to its invasive nature and
its anatomical characteristics.
Systemic chemotherapy is usually indicated for patients with
unresectable, advanced BTC or for those who have relapsed after
operation; however, no standard treatment has yet been estab-
lished for such patients. Gemcitabine hydrochloride is a
deoxycytidine derivative that inhibits DNA elongation through
intracellular phosphorylation of ribonucleotide reductase. In
Japan, a single-arm Phase II study in patients with unresectable
BTC confirmed that gemcitabine monotherapy had moderate
efficacy and manageable toxicity, both of which were comparable
with approved treatments for other cancers (Okusaka et al, 2006).
As gemcitabine had also been found to exhibit synergistic effects
on cytotoxic activity in vitro and in vivo when combined with
cisplatin (Peters et al, 1995; Bergman et al, 1996), clinical studies
were conducted in various cancers with this combination. Results
from these studies eventually led to use of the gemcitabine plus
cisplatin (GC) combination as one of the standard treatments for
non-small cell lung cancer and bladder cancer.
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researchers for the treatment of BTC (Park et al, 2006; Eckel and
Schmid, 2007; Pasetto et al, 2007; Lee et al, 2008). So far, the largest
randomised Phase III study has been the recent UK ABC-02 study,
in which the efficacy and safety of gemcitabine 1000mgm
 2 alone
vs the combination of gemcitabine 1000mgm
 2 plus cisplatin
25mgm
 2 was evaluated by British research groups (Cancer
Research UK and University College London). That study was
initiated as a randomised phase II study with gemcitabine alone vs
GC (UK ABC-01 study) and then was expanded to a phase III study
(ABC-02 study) (Valle et al, 2009a,b).
Our study was planned to follow-up on an earlier study of
gemcitabine monotherapy conducted in Japanese BTC patients
(Okusaka et al, 2006). Given the encouraging results from the UK
ABC-01 study, we conducted this study to (1) evaluate both
gemcitabine monotherapy and the GC combination in Japanese
BTC patients, and (2) determine whether benefits similar to those
observed in the UK study could be obtained for the combination
regimen.
The primary objective of the study was to compare the 1-year
survival rate in patients with BTC who received one of these two
therapies. The secondary objectives included response rate,
progression-free survival (PFS) and assessment of safety.
MATERIALS AND METHODS
Study design
This was a multicentre, randomised phase II study to evaluate the
efficacy and safety of GC combination compared with single-agent
gemcitabine in chemotherapy-naive patients with locally advanced
or metastatic BTC. Patients were randomised to either single-agent
gemcitabine 1000mgm
 2 on days 1, 8 and 15 of a 28-day cycle (G-arm)
or cisplatin 25mgm
 2 followed by gemcitabine 1000mgm
 2 on
days 1, 8 of a 21-day cycle (GC-arm). Randomisation was stratified
by primary site (gallbladder cancer or other BTC) and the presence
or absence of primary tumour.
Eligibility criteria
Eligible patients met the following criteria: histologically con-
firmed unresectable locally advanced or metastatic cancer of the
biliary tract; no history of earlier chemotherapy; performance
status of 0 or 1; a life expectancy of at least 3 months; at least
20 years of age at the time of study entry; adequate function of
major organs (haemoglobin X10g per 100ml, white blood cells
X3000/mm
3, neutrophils X1500/mm
3, platelets X100000/mm3,
AST/ALT/ALP p3 times upper limit of normal (ULN), total
bilirubin p2 times ULN, p3 times ULN for patients with
obstructive jaundice or metastases to the liver, serum creatinine
p1.5 times ULN, creatinine clearance or 24-h creatinine clearance
X45mlmin
 1).
This study followed the ethical principles that have their origins
in the Declaration of Helsinki, and was conducted in accordance
with the protocol, the ‘ordinance on Good Clinical Practice’ and
related regulations. Written informed consent was obtained from
all patients who were considered eligible for participation in this
study before enrolment. The Efficacy and Safety Evaluation
Committee, an independent review board, was consulted if any
efficacy and safety issues arose in the study.
Study treatment
The assigned treatment was given for a minimum of 12 weeks
(at least four cycles in the GC-arm and three cycles in the G-arm)
and continued to a maximum of 48 weeks (up to 16 cycles in
the GC-arm and up to 12 cycles in the G-arm), unless disease
progression (PD) was evident, an intolerable adverse event
occurred or the patient was required to withdraw from the study.
Efficacy and safety assessment
All patients who received at least 1 dose of the study drug were
included in the efficacy and safety assessment. Response rate was
evaluated according to the Response Evaluation Criteria in Solid
Tumors. Evaluation of tumours after patient randomisation was
performed every 6 weeks until PD. Adverse events were graded
according to the Common Terminology Criteria for Adverse
Events, version 3.0 (CTCAE v3.0).
Statistical design and analysis
The sample size was calculated by the selection method of Simon
(Simon et al, 1985), which is based on the proposition that GC
combination therapy is selected if the 1-year survival rate for the
GC-arm is higher than that for the gemcitabine arm. We assumed a
1-year survival rate of 25% for the G-arm and 35% for GC-arm
(Okusaka et al, 2006; Park et al, 2006). With these assumptions, 30
patients per arm were needed to appropriately select the
combination therapy with a probability of X80%. To optimise
safety and efficacy information, the sample size was set to 42
patients per arm.
The Kaplan–Meier method was used to estimate 1-year survival
(primary outcome), PFS and 6-month PFS rates (secondary
outcomes) for each treatment arm; 95% confidence intervals
(CIs) were calculated. A Cox proportional hazards model was used
to calculate the hazard ratio, 95% CI and its two-tailed P-value.
Fisher’s exact test was used to compare the patient characteristics,
response and disease control rates, and toxicities between the two
treatment arms. The exact CIs were calculated based on binomial
distributions.
RESULTS
Patients
This study was carried out from September 2006 to October 2008
at nine study centres in Japan. Eighty-four patients were
randomised to either gemcitabine monotherapy (G-arm) or GC
combination (GC-arm). One patient assigned to the GC-arm was
not treated because the general condition of the patient
deteriorated before study treatment. All of the remaining 83
patients, 41 in the GC-arm and 42 in the G-arm, received at least 1
dose of study treatment. Efficacy and safety were evaluated for
each of these 83 patients (Figure 1). Demographic variables
(Table 1) were well balanced between the two treatment arms,
except for patients with ampullary carcinoma (4 in GC-arm, 0 in
G-arm).
Drug exposure and duration of the treatments
A total of 247 (median 6.0) and 203 (median 4.0) cycles were
administered in the GC-arm and G-arm, respectively. Relative dose
intensities were 78.9% for gemcitabine and 79.0% for cisplatin in
the GC-arm, and 87.4% for gemcitabine in the G-arm. Three
patients in the GC-arm and two patients in the G-arm completed
48 weeks treatment.
Efficacy
A total of 83 patients were evaluable for tumour response
according to the protocol, 41 in the GC-arm and 42 in the
G-arm. No complete tumour responses were observed. In total,
eight patients in the GC-arm had a partial response (PR) compared
with five patients in the G-arm (PR 19.5 vs 11.9%). In addition,
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G-arm (SD 48.8 vs 38.1%). The disease control rate (CRþPRþSD)
was 68.3% (95% CI: 51.9, 81.9) vs 50.0% (95% CI: 34.2, 65.8) in
favour of the combination therapy. The 1-year survival rate (39.0
vs 31.0%), median survival time (11.2 months vs 7.7 months) and
median PFS (5.8 months vs 3.7 months) were better for the GC-arm
vs G-arm (Figure 2). The hazard ratio between the GC and G-arms
was 0.69 (95% CI: 0.42, 1.13) for overall survival (OS) and 0.66
(95% CI: 0.41, 1.05) for PFS (Table 2).
As shown in Table 3, the prognosis for patients with gallbladder
cancer was worse than that for patients with non-gallbladder
cancer; however, the median survival times were longer with the
GC combination in gallbladder cancer patients (9.1 months vs 6.7
months), as well as in patients with non-gallbladder cancer (13.0
months vs 8.0 months). The prognosis for patients with primary
tumours was worse than that for patients without primary
tumours; however, the GC therapy showed longer median survival
time in both patient subgroups (9.4 months vs 7.4 months in the
patients with primary tumours, 16.1 months vs 12.7 months in the
patients without primary tumours).
Safety
All adverse events observed in this study were predictable and
manageable based on the safety profile of GC. As shown in Table 4,
the most common grade 3 or higher adverse events (X25%) were
neutropenia (56.1%), thrombocytopenia (39.0%), haemoglobin
decrease (36.6%), RBC decrease (34.1%), leukopenia (29.3%) and
g-GTP increase (29.3%) in the GC-arm, and neutropenia (38.1%)
and g-GTP increase (35.7%) in the G-arm. The incidence of
haematotoxicity was higher in the GC-arm; grade 3 or more
serious C-reactive protein increase was detected only in the
monotherapy arm.
There were no treatment related deaths. Most of the patients
recovered from the above adverse events by reducing or
discontinuing the study treatment.
Table 1 Patient characteristics
GC (N¼41) GEM (N¼42)
Characteristic n (%) n (%) P-value
Gender
Male 18 (43.9) 21 (50.0) 0.662
Female 23 (56.1) 21 (50.0)
Age (year)
Median 65.0 66.5 0.0812
a
Range 43–80 49–78
PS
0 34 (82.9) 28 (66.7) 0.129
1 7 (17.1) 14 (33.3)
Primary tumour sites
Extraheptic bile duct 8 (19.5) 11 (26.2) 0.239
Intraheptic bile duct 14 (34.1) 14 (33.3)
Gallbladder 15 (36.6) 17 (40.5)
Ampulla 4 (9.8) 0 (0.0)
Metastatic sites
Liver 22 (53.7) 20 (47.6) 0.663
Regional lymph nodes 23 (56.1) 28 (66.7) 0.372
Distant lymph nodes 19 (46.3) 18 (42.9) 0.827
Lung 8 (19.5) 7 (16.7) 0.782
Peritoneum 7 (17.1) 7 (16.7) 1.000
Bone 0 (0.0) 1 (2.4) 1.000
Others 3 (7.3) 3 (7.1) 1.000
Initial onset or recurrence
Initial onset 30 (73.2) 32 (76.2) 0.804
Recurrence after surgery 11 (26.8) 10 (23.8)
Histological type
Adenocarcinoma 39 (95.1) 41 (97.6) 0.616
Adenosquamous cancer 2 (4.9) 1 (2.4)
Disease stage (gallbladder cancer, extrahepatic bile duct cancer, ampulla cancer)
IIA 0 (0.0) 0 (0.0) 1.000
IIB 3 (7.3)
b 2 (4.8)
b
III 2 (4.9) 2 (4.8)
IV 16 (39.0) 17 (40.5)
Recurrence after surgery 6 (14.6) 7 (16.7)
Disease stage (intrahepatic bile duct cancer)
II 0 (0.0) 1 (2.4)
b 0.389
IIIA 0 (0.0) 1 (2.4)
IIIB 0 (0.0) 0 (0.0)
IIIC 0 (0.0) 2 (4.8)
IV 9 (22.0) 7 (16.7)
Recurrence after surgery 5 (12.2) 3 (7.1)
Biliary drainage
No 25 (61.0) 24 (57.1) 0.824
Yes 16 (39.0) 18 (42.9)
Previous therapy
No 30 (73.2) 28 (66.7) 0.855
Surgery 11 (26.8) 12 (28.6)
Radiotherapy 0 (0.0) 1 (2.4)
Surgery and radiotherapy 0 (0.0) 1 (2.4)
Abbreviations: GC¼gemcitabine and cisplatin; GEM¼gemcitabine; PS¼perfor-
mance status.
at-test.
bPatients were diagnosed as having unresectable disease with
marked regional node metastases involving the proper hepatic artery and/or main
portal vein.
Randomised
(N=84)
GC
(n=42)
Patient not treated (n=1)
Eligible for efficacy and
safety analyis
Eligible for efficacy and
safety analyis
GC
(n=41)
Reasons for discontinuation
Progression of disease
Unable to start next cycle
Adverse event
Patient decision
Physician decision
Completed study (48 weeks) 3
1
1
0
3
3
0
34 25
7
4
2
GC arm GEM arm
GEM
(n=42)
· Deterioration of general condition
  before study treatment
GEM
(n=42)
Figure 1 CONSORT diagram. Disposition of patients. GC¼gemcita-
bine–cisplatin combination; GEM¼gemcitabine alone.
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Thirty patients in the GC-arm received post-study chemotherapy
including S-1, tegaful/gimeracil/oteracil potassium (19 patients),
gemcitabine (10 patients) and tegaful/uracil (1 patient). In the
G-arm, 33 patients received post-study chemotherapy including
S-1 (20 patients), gemcitabine (11 patients), cisplatin/fluorouracil
(1 patient) and doxorubicin/tegaful/uracil (1 patient).
DISCUSSION
Although this study (BT22 study) showed that gemcitabine
monotherapy and the GC combination were both active in
Japanese patients with advanced BTC, a superior benefit was
obtained with the combination treatment. In the GC/G-arms, the
1-year survival rate was 39.0%/31.0%, median survival time was
11.2/7.7 months and median PFS time was 5.8/3.7 months
(Table 2).
The UK ABC-02 study, which was conducted with the same dose
and regimen as this study (Valle et al, 2009b), showed a similar
benefit for the GC combination. The respective median survival/
PFS times in that study were 11.7/8.5 months in their GC-arm, and
8.2/6.5 months in their G-arm.
The hazard ratios reported in the ABC-02 study for OS (0.68,
95% CI: 0.53, 0.86) and PFS (0.70, 95% CI: 0.56, 0.88) compared
well with the respective values from our study: 0.69 (95% CI: 0.42,
1.13) and 0.66 (95% CI: 0.41, 1.05). As the number of patients was
based on Simon’s selection method (Simon et al, 1985), this study
was not designed to compare and identify statistical significant
differences between the two treatment arms. These hazard ratios
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Figure 2 Kaplan–Meier curve of overall survival and progression-free
survival. (A) Overall survival. (B) Progression-free survival. GC¼gemcita-
bine–cisplatin combination; GEM¼gemcitabine alone; CI¼confidence
interval.
Table 2 Summary of time-to-event end points: overall response and survival
GC (N¼41) GEM (N¼42)
n (%) n (%) P-value
Overall response rate
Complete response (CR) 0 (0.0) 0 (0.0)
Partial response (PR) 8 (19.5) 5 (11.9)
Stable disease (SD) 20 (48.8) 16 (38.1)
Progressive disease (PD) 9 (22.0) 17 (40.5)
Not evaluable (NE) 4 (9.8) 4 (9.5)
Response rate (95% CI) 19.5% (8.8, 34.9) 11.9% (4.0, 25.6) 0.380
Disease control rate (CR+PR+SD) (95% CI) 68.3% (51.9, 81.9) 50.0% (34.2, 65.8) 0.119
Overall survival
1-year survival rate (95% CI) 39.0% (23.7, 54.4) 31.0% (17.0, 44.9)
Median survival time (95% CI) 11.2 months (9.1, 12.5) 7.7 months (6.1, 11.0)
Hazard ratio (95% CI) 0.69 (95% CI: 0.42, 1.13) 0.139
Progression-free survival (PFS)
Median PFS (95% CI) 5.8 months (4.1, 8.2) 3.7 months (2.1, 5.3)
Hazard ratio (95% CI) 0.66 (95%CI: 0.41, 1.05) 0.077
6-Months PFS rate (95% CI) 47.4% (31.4, 63.4) 27.7% (14.0, 41.5)
Abbreviations: GC¼gemcitabine and cisplatin; GEM¼gemcitabine; CI¼confidence interval.
Table 3 Overall survival time by stratification factor
Median survival
time (months)
(95% CI) GC (N¼41) GEM (N¼42) P-value
Tumour site
Gallbladder 9.1 (6.9, 11.6) 6.7 (4.2, 11.0) 0.675
Non-gallbladder 13.0 (9.2, ***) 8.0 (6.1, 16.0) 0.110
Primary tumour
Presence of primary tumour 9.4 (8.7, 11.6) 7.4 (5.9, 8.5) 0.253
Absence of primary tumour 16.1 (12.3, ***) 12.7 (6.5, ***) 0.389
Abbreviations: GC¼gemcitabine and cisplatin; GEM¼gemcitabine; CI¼confidence
interval. ***denotes upper limits are not available.
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compared with single-agent gemcitabine, even though there were
no statistical significant differences in survival and PFS between
the two arms in our study.
Although there have been many single-arm Phase II studies of
the GC combination for BTC (Thongprasert et al, 2005; Kim et al,
2006; Charoentum et al, 2007; Meyerhardt et al, 2008; Valle et al,
2009a), these results have never been distilled to one fixed dose
and regimen of GC. Many previous studies of GC combination
reported relatively higher response rates, but with more serious
treatment-related adverse events (Thongprasert et al, 2005; Kim
et al, 2006; Charoentum et al, 2007; Meyerhardt et al, 2008). In the
phase II study conducted by Thongprasert et al (2005), 17.85% of
the patients who were treated with the GC combination required
dose reduction, and in another Phase II study recently conducted
by Meyerhardt et al (2008), dose reductions and study withdrawals
were required for 50% of the patients who received the
combination therapy. In our study, we also observed more
frequent adverse events with the doublet (Table 4). However, as
shown in Figure 1, only seven patients (17%) discontinued from
the study because of adverse events and four patients (9.7%)
required dose adjustments in the GC-arm.
Overall, the toxicity observed in this study was manageable.
Although interstitial pneumonia was detected in one patient from
each of the arms, both patients recovered with appropriate
treatment. One grade 3 renal failure and one grade 2 peripheral
neuropathy were observed in GC-arm, in line with similar events
seen in previous studies of the GC combination (Thongprasert
et al, 2005; Kim et al, 2006; Charoentum et al, 2007; Meyerhardt
et al, 2008; Valle et al, 2009a). It is to be noted that despite the
higher incidence of haematotoxicity in patients receiving
the combination therapy, drug-caused myelosuppression did not
result in febrile neutropenia or bleeding. Grade 3 or greater
increases in C-reactive protein were observed only in the
gemcitabine monotherapy-arm, also suggesting that the combina-
tion therapy did not increase neutropenic infections.
In this study, we stratified patients into those with gallbladder
cancer and those with other BTCs. Gallbladder cancer has been
reported to have a different biological behaviour (Kim et al, 2006;
Doval et al, 2004; Jarnagin et al, 2006); furthermore, a pooled
analysis by Eckel and Schmid (2007) revealed a higher response
rate to chemotherapy and shorter OS for gallbladder cancer
compared with other BTCs. As shown in Table 3, patients with
gallbladder cancer showed worse survival than patients with other
BTCs, this being consistent with previous reports (Eckel and
Schmid, 2007; Wagner et al, 2009). It is important to note that
median survival times were longer with the GC combination in
patients with gallbladder cancer (9.1 months vs 6.7 months), as
well as in patients with non-gallbladder cancer (13.0 months vs 8.0
months), suggesting that the combination therapy has greater
benefit than monotherapy in gallbladder cancer and other BTC
patients.
Another stratification factor used for this study was the presence
or absence of a primary tumour, not a commonly used
stratification factor in clinical trials for advanced BTC. Locally
advanced or metastatic cancer, the stratification factor used in the
UK ABC-01 and UK ABC-02 studies, is more commonly used, as
both of these have been shown to affect OS in advanced BTC (Park
et al, 2009). However, considering the importance of surgical
resection of the primary tumour, we decided to use this as a
stratification factor for patients in this study. As shown in Table 3,
patients with primary tumours showed remarkably worse survival
than patients without primary tumours. However, because of the
limited number of patients in our subanalyses, the results should
be viewed with caution, and the usefulness of this prognostic factor
should be evaluated in future studies. We will continue our efforts
Table 4 Summary of maximum toxicity grades
a (incidence X30%)
GC (N¼41) GEM (N¼42)
Maximum toxicity grade Maximum toxicity grade
Events Grade 3 (%) Grade 4 (%) All grades (%) Grade 3 (%) Grade 4 (%) All grades (%) P-value
Haematological
WBC count decreased 29.3 0 87.8 19.0 0 69.0 0.061
Haemoglobin decreased 26.8 9.8 85.4 9.5 7.1 85.7 1.000
Neutrophil count decreased 39.0 17.1 82.9 28.6 9.5 69.0 0.200
Platelet count decreased 26.8 12.2 80.5 4.8 2.4 76.2 0.791
RBC decreased 34.1 0 75.6 14.3 0 78.6 0.798
Haematocrit decreased 4.9 0 58.5 0 0 54.8 0.826
Non-haematological
Anorexia 0 0 80.5 4.8 0 61.9 0.090
Nausea 0 0 68.3 0 0 42.9 0.027
Fatigue 0 0 58.5 2.4 0 50.0 0.511
AST increased 17.1 0 53.7 14.3 2.4 52.4 1.000
ALT increased 24.4 0 51.2 16.7 0 52.4 1.000
Vomiting 0 0 48.8 0 0 23.8 0.023
GGT increased 29.3 0 46.3 31.0 4.8 50.0 0.827
Pyrexia 0 0 43.9 4.8 0 57.1 0.190
LDH increased 0 0 36.6 0 0 35.7 1.000
Constipation 0 0 36.6 0 0 33.3 0.820
ALP increased 7.3 0 31.7 16.7 0 40.5 0.495
Weight decreased 0 0 31.7 0 0 31.0 1.000
Diarrhoea 2.4 0 31.7 0 0 26.2 0.634
Blood sodium decreased 17.1 0 31.7 9.5 0 19.0 0.214
C-reactive protein increased 0 0 26.8 7.1 0 52.4 0.025
Abbreviations: ALP¼alkaline phosphatase; ALT¼alanine aminotransferase; AST¼aspartate aminotransferase; GC¼gemcitabine and cisplatin; GEM¼gemcitabine; GGT¼
g-glutamyltransferase; LDH¼lactate dehydrogenase; RBC¼red blood cell; WBC¼white blood cell.
aEvents were graded according to CTCAE v3.0.
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prognostic factors in a larger population, which may significantly
affect clinical studies in BTC.
Despite the heterogeneous nature of BTC and the ethnic
differences reported for this tumour type (Goodman and
Yamamoto, 2007; Aljiffry et al, 2009), the outcomes from this
study showed striking similarity with the large-scale phase III
study (UK ABC-02) results. This suggests that cisplatin 25mgm
 2
plus gemcitabine 1000mgm
 2 on days 1 and 8 of a 21-day cycle
would be beneficial in the treatment of advanced BTC.
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